About | Free Trial

Last Update

2016-05-09T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Norman Kneteman?

Dr. Norman Kneteman M.

Professor and Division Director of Transplantation Surgery

University of Alberta

Direct Phone: (780) ***-****       

University of Alberta

2-45 Medical Sciences Building

Edmonton, Alberta T6G 2H7

Canada

Company Description

About the University of Alberta's Faculty of Engineering (www.engineering.ualberta.ca) The UofA's Faculty of Engineering is one of the largest and most accomplished engineering research and teaching centers. With 4,100 students, 20 research chairs, 100 ne ... more

Find other employees at this company (21,304)

Background Information

Employment History

President and Chief Executive Officer
KMT Hepatech Inc

Zone Clinical Section Chief Transplantation
Alberta Health Services

Affiliations

Scientific Advisory Board Member
Isotechnika Inc.

Executive Member
National Organizing Committee

Education

Doctor of Medicine with Distinction
Experimental Surgery
University of Alberta

MSc

Master of Science
Experimental Surgery
University of Alberta

Web References (184 Total References)


Course Detail

www.camenaegroup.com [cached]

Norman Kneteman, MD

Professor of Surgery
Director, Division of Transplantation
University of Alberta Hospital • Edmonton, Canada
...
Norman Kneteman, MD (10:20)


Course Detail

camenaegroup.com [cached]

Norman Kneteman, MD

Professor of Surgery
Director, Division of Transplantation
University of Alberta Hospital • Edmonton, Canada
...
Norman Kneteman, MD (10:20)


In 2001, a team of researchers ...

www.kmthepatech.com [cached]

In 2001, a team of researchers led by the University of Alberta's Norman Kneteman developed a mouse model with a humanized liver and became the first group to infect liver-humanized mice with hepatitis C. The researchers started with immunodeficient mice engineered to express a transgene that kills liver cells. They then surgically implanted human hepatocytes into the dying mouse liver. Because of the liver's natural regenerative capacity, the cells thrived and multiplied, leaving the mice with functional new livers that were partly human -and readily infected with hepatitis C. The access to this liver-chimeric mouse is now available through KMT Hepatech, an Alberta, Canada-based company co-founded by Kneteman.


Dr. Norman Kneteman, President and CEO - KMT Hepatech - University of Alberta

www.kmthepatech.com [cached]

Dr. Norman Kneteman, President and CEO

...
Home > About Us > Management > Dr Norman Kneteman
...
Dr. Norman Kneteman, President and CEO
...
Dr. Norman Kneteman
Dr. Norman Kneteman, MD, MSc, FRCSC, FACS, MS, is a Professor in the Department of Surgery at the University of Alberta and the Director of the Regional Clinical Programs in Transplantation and the Liver Transplant Program for Capital Health Authority. As the co-founder, President and CEO of KMT Hepatech, Inc., he carries overall responsibility for the conducted services and research. He held the CIHR (Canadian Institutes for Health Research) / Wyeth Chair in Transplantation Research. Dr. Kneteman received his Doctor of Medicine with Distinction and Master of Science in Experimental Surgery from the University of Alberta.
Dr. Kneteman is a recipient of 40 Awards and Honors, author and co-author of 21 book chapters, 171 peer reviewed papers and 23 patents.


ATC Post 2012

atc-365.ascendeventmedia.com [cached]

Norman Kneteman, MD The symposium also featured Norman Kneteman, MD, Adjunct Professor, University of Alberta, Edmonton, Alberta. He addressed post-transplant strategies to avoid recurrent HCC. Primarily, evidence points to mTOR immunosuppression (sirolimus or everolimus) as a strategy to prevent HCC recurrence after transplantation.

"A series of in vitro data in animal studies, some retrospective reviews, a meta-analysis from those reviews and a review of the Scientific Registry of Transplant Recipients database all support a role for mTOR inhibitors in improving outcomes after liver transplant for HCC," he said.
Dr. Kneteman also reported that sorafenib enhances the anti-tumor activity of rapamycin in HCC.

Similar Profiles

Other People with this Name

Other people with the name Kneteman

Ross Kneteman

Kelsey Kneteman
I'm for Kids Team

Lindsay Kneteman
Massey Hall

Christie Kneteman
Torys LLP

Barbara Kneteman
Evergreen Catholic Separate Regional Division

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory